

BEXSERO- neisseria meningitidis serogroup b nhba fusion protein antigen, neisseria meningitidis serogroup b fhbp fusion protein antigen and neisseria meningitidis serogroup b nada protein antigen injection, suspension
GlaxoSmithKline Biologicals SA

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use BEXSERO safely and effectively. See full prescribing information for BEXSERO.

BEXSERO (Meningococcal Group B Vaccine)
suspension for intramuscular injection

Initial U.S. Approval: 2015

----- **RECENT MAJOR CHANGES** -----

Warnings and Precautions, Altered Immunocompetence (5.5)

5/2018

----- **INDICATIONS AND USAGE** -----

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age. (1)
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed. (1)

----- **DOSAGE AND ADMINISTRATION** -----

For intramuscular use only. (2)

Administer 2 doses (0.5-mL each) of BEXSERO at least 1 month apart. (2.1)

----- **DOSAGE FORMS AND STRENGTHS** -----

Suspension for intramuscular injection in 0.5-mL single-dose prefilled syringes. (3)

----- **CONTRAINDICATIONS** -----

Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO. (4)

----- **WARNINGS AND PRECAUTIONS** -----

The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals. (5.3)

----- **ADVERSE REACTIONS** -----

The most common solicited adverse reactions observed in clinical trials were pain at the injection site ($\geq 83\%$), myalgia ($\geq 48\%$), erythema ($\geq 45\%$), fatigue ($\geq 35\%$), headache ($\geq 33\%$), induration ($\geq 28\%$), nausea ($\geq 18\%$), and arthralgia ($\geq 13\%$). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or <http://www.vaers.hhs.gov>.

----- **USE IN SPECIFIC POPULATIONS** -----

- **Pregnancy:** BEXSERO should be used during pregnancy only if clearly needed. Pregnancy registry available for BEXSERO. Register women who receive BEXSERO while pregnant in the pregnancy registry by calling 1-877-413-4759. (8.1)

See 17 for **PATIENT COUNSELING INFORMATION**.

Revised: 5/2018

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Dose and Schedule

2.2 Administration

2.3 Use of BEXSERO with other Meningococcal Group B Vaccines

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Preventing and Managing Allergic Reactions

5.2 Syncope

5.3 Latex

5.4 Limitation of Vaccine Effectiveness

5.5 Altered Immunocompetence

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Additional Pre-licensure Safety Experience

6.3 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

13 NONCLINICAL TOXICOLOGY

14 CLINICAL STUDIES

14.1 Immunogenicity

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

2 DOSAGE AND ADMINISTRATION

For intramuscular use only.

2.1 Dose and Schedule

Administer 2 doses (0.5-mL each) of BEXSERO at least 1 month apart.

2.2 Administration

Shake the syringe immediately before use to form a homogeneous suspension. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is found.

Administer BEXSERO as a 0.5-mL intramuscular injection into the deltoid muscle of the upper arm.

2.3 Use of BEXSERO with other Meningococcal Group B Vaccines

Sufficient data are not available on the safety and effectiveness of using BEXSERO and other meningococcal group B vaccines interchangeably to complete the vaccination series.

3 DOSAGE FORMS AND STRENGTHS

BEXSERO is a suspension for intramuscular injection in 0.5-mL single-dose prefilled syringes.

4 CONTRAINDICATIONS

Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO [see Description (11)].

5 WARNINGS AND PRECAUTIONS

5.1 Preventing and Managing Allergic Reactions

Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine.

5.2 Syncope

Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope.

5.3 Latex

The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions in latex-sensitive individuals.

5.4 Limitation of Vaccine Effectiveness

BEXSERO may not protect all vaccine recipients. BEXSERO may not provide protection against all meningococcal serogroup B strains [see Clinical Pharmacology (12.1)].

5.5 Altered Immunocompetence

Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO.

Complement Deficiency

Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *N. meningitidis* serogroup B even if they develop antibodies following vaccination with BEXSERO. [See Clinical Pharmacology (12.1).]

6 ADVERSE REACTIONS

The most common solicited adverse reactions observed in clinical trials were pain at the injection site

(≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

In 4 clinical trials, 3,058 individuals aged 10 through 25 years received at least one dose of BEXSERO, 1,436 participants received only BEXSERO, 2,089 received only placebo or a control vaccine, and 1,622 participants received a mixed regimen (placebo or control vaccine and BEXSERO).

In a randomized controlled study¹ conducted in U.S. and Poland, 120 participants aged 10 through 25 years received at least 1 dose of BEXSERO, including 112 participants who received 2 doses of BEXSERO 2 months apart; 97 participants received saline placebo followed by MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine]. Across groups, median age was 13 years, males comprised 49%, and 60% were white; 34% were Hispanic, 4% were black, <1% were Asian, and 2% were other.

In a second randomized controlled study² conducted in Chile, all subjects (N = 1,622) aged 11 through 17 years received at least 1 dose of BEXSERO. This study included a subset of 810 subjects who received 2 doses of BEXSERO 1 or 2 months apart. A control group of 128 subjects received at least 1 dose of placebo containing aluminum hydroxide. A subgroup of 128 subjects received 2 doses of BEXSERO 6 months apart. In this study, median age was 14 years, males comprised 44%, and 99% were Hispanic.

In a third randomized controlled study³ conducted in the United Kingdom (U.K.), 974 university students aged 18 through 24 years received at least 1 dose of BEXSERO, including 932 subjects who received 2 doses of BEXSERO 1 month apart. Comparator groups received 1 dose of MENVEO followed by 1 dose of placebo containing aluminum hydroxide (n = 956) or 2 doses of IXIARO (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) (n = 947). Across groups, median age was 20 years, males comprised 46%, and 88% were white, 5% were Asian, 2% were black, <1% were Hispanic, and 4% were other.

In an uncontrolled study⁴ conducted in Canada and Australia, 342 participants aged 11 through 17 years received at least 1 dose of BEXSERO, including 338 participants who received 2 doses of BEXSERO 1 month apart. The median age was 13 years, males comprised 55%, and 80% were white, 10% were Asian, 4% were Native American/Alaskan, and 4% were other.

Local and systemic reactogenicity data were solicited from all participants in the studies conducted in Chile, U.S./Poland, Canada/Australia, and in a subset of participants in the U.K. study. Reports of unsolicited adverse events occurring within the first 7 days after each vaccination were collected in all studies. In the U.S./Poland study, reports of unsolicited adverse events were collected up to 1 month after the second vaccination.

Reports of all serious adverse events, medically attended adverse events, and adverse events leading to premature withdrawal were collected throughout the study period for the studies conducted in Chile (12 months), U.K. (12 months), U.S./Poland (8 months), and Canada/Australia (2 months).

Solicited Adverse Reactions

The reported rates of local and systemic reactions among participants aged 10 through 25 years following each dose of BEXSERO administered 2 months apart or control in the U.S./Polish study¹ are presented in Table 1 and Table 2.

Table 1. Percentage of U.S. and Polish Participants Aged 10 through 25 Years Reporting Local Solicited Adverse Reactions^a within 7 Days after BEXSERO or Control, by Dose

		Dose 1		
--	--	--------	--	--

Local Adverse Reaction	Dose 1 BEXSERO n = 110-114	Placebo (Saline) n = 94-96	Dose 2^b BEXSERO n = 107-109	Dose 2^b MENVEO n = 90-92
Pain - Any	90	27	83	43
Pain - Mild	27	20	18	26
Pain - Moderate	44	5	37	9
Pain - Severe	20	2	29	8
Erythema - Any	50	13	45	26
Erythema - 1-25 mm	41	11	36	13
Erythema - >25-50 mm	6	1	5	6
Erythema - >50-100 mm	3	0	5	4
Erythema - >100 mm	0	0	0	2
Induration - Any	32	10	28	23
Induration - 1-25 mm	24	9	22	16
Induration - >25-50 mm	7	0	4	0
Induration - >50-100 mm	1	1	2	4
Induration - >100 mm	0	0	0	2

Clinicaltrials.gov Identifier NCT01272180.

^a Erythema and induration: Any (≥ 1 mm). Pain: Mild (transient with no limitation in normal daily activity); Moderate (some limitation in normal daily activity); Severe (unable to perform normal daily activity).

^b Administered 2 months after Dose 1.

Table 2. Percentage of U.S. and Polish Participants Aged 10 through 25 Years Reporting Systemic Adverse Reactions^a within 7 Days after BEXSERO or Control, by Dose

Systemic Adverse Reaction	Dose 1 BEXSERO n = 110-114	Dose 1 Placebo (Saline) n = 94-96	Dose 2^b BEXSERO n = 107-109	Dose 2^b MENVEO n = 90-92
Fatigue - Any	37	22	35	20
Fatigue - Mild	19	17	18	11
Fatigue - Moderate	14	5	10	7
Fatigue - Severe	4	0	6	2
Nausea - Any	19	4	18	4
Nausea - Mild	12	3	10	3
Nausea - Moderate	4	1	5	1
Nausea - Severe	4	0	4	0
Myalgia - Any	49	26	48	25
Myalgia - Mild	21	20	16	14
Myalgia - Moderate	16	5	19	7
Myalgia - Severe	12	1	13	4
Arthralgia - Any	13	4	16	4
Arthralgia - Mild	9	3	8	2
Arthralgia - Moderate	3	1	6	2
Arthralgia - Severe	2	0	2	0
Headache - Any	33	20	34	23

Headache - Mild	19	15	21	8
Headache - Moderate	9	4	6	12
Headache - Severe	4	1	6	3
Fever - $\geq 38^{\circ}\text{C}$	1	1	5	0
Fever - $38.0\text{-}38.9^{\circ}\text{C}$	1	1	4	0
Fever - $39.0\text{-}39.9^{\circ}\text{C}$	0	0	1	0
Fever - $\geq 40^{\circ}\text{C}$	0	0	0	0

Clinicaltrials.gov Identifier NCT01272180.

^a Systemic reactions: Mild (transient with no limitation in normal daily activity); Moderate (some limitation in normal daily activity); Severe (unable to perform normal daily activity).

^b Administered 2 months after Dose 1.

Solicited adverse reaction rates were similar among participants aged 11 through 24 years who received BEXSERO in the other 3 clinical studies,^{2,3,4} except for severe myalgia which was reported by 3% to 7% of subjects. Severe pain was reported by 8% of university students in the U.K.³

Non-serious Adverse Events

In the 3 controlled studies^{1,2,3} (BEXSERO n = 2,221, control n = 2,204), non-serious unsolicited adverse events that occurred within 7 days of any dose were reported by 439 (20%) participants receiving BEXSERO and 197 (9%) control recipients. Unsolicited adverse events that were reported among at least 2% of participants and were more frequently reported in participants receiving BEXSERO than in control recipients were injection site pain, headache, injection site induration unresolved within 7 days, and nasopharyngitis.

Serious Adverse Events

Overall, in clinical studies, among 3,058 participants aged 10 through 25 years who received at least 1 dose of BEXSERO, 66 (2.1%) participants reported serious adverse events at any time during the study. In the 3 controlled studies^{1,2,3} (BEXSERO n = 2,716, control n = 2,078), serious adverse events within 30 days after any dose were reported in 23 (0.8%) participants receiving BEXSERO and 10 (0.5%) control recipients.

6.2 Additional Pre-licensure Safety Experience

In response to outbreaks of serogroup B meningococcal disease at 2 universities in the U.S., BEXSERO was administered as a 2-dose series at least 1 month apart. Information on serious adverse events was collected for a period of 30 days after each dose from 15,351 individuals aged 16 through 65 years who received at least 1 dose. Overall 50 individuals (0.3%) reported serious adverse events, including one event considered related to vaccination, a case of anaphylaxis within 30 minutes following vaccination.

6.3 Postmarketing Experience

Adverse event reports received for BEXSERO marketed outside the U.S. are listed below. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency, or to establish a causal relationship to vaccination. This list includes serious events or events which have suspected causal association to BEXSERO.

General Disorders and Administration Site Conditions

Injection site reactions (including extensive swelling of the vaccinated limb, blisters at or around the injection site, and injection site nodule which may persist for more than 1 month).

Immune System Disorders

Allergic reactions (including anaphylactic reactions), rash, eye swelling.

Nervous System Disorders

Syncope, vasovagal responses to injection.

7 DRUG INTERACTIONS

Sufficient data are not available to establish the safety and immunogenicity of concomitant administration of BEXSERO with recommended adolescent vaccines.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B.

Reproduction studies have been performed in rabbits at doses up to 15 times the human dose on a body-weight basis and have revealed no evidence of impaired fertility in females or harm to the fetus due to BEXSERO. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, BEXSERO should be used during pregnancy only if clearly needed.

Pregnancy Registry for BEXSERO

GlaxoSmithKline maintains a surveillance registry to collect data on pregnancy outcomes and newborn health status outcomes following exposure to BEXSERO during pregnancy. Women who receive BEXSERO during pregnancy should be encouraged to contact GlaxoSmithKline directly or their healthcare provider should contact GlaxoSmithKline by calling 1-877-413-4759.

8.3 Nursing Mothers

It is not known whether BEXSERO is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BEXSERO is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of BEXSERO have not been established in children younger than 10 years.

8.5 Geriatric Use

Safety and effectiveness of BEXSERO have not been established in adults older than 65 years.

11 DESCRIPTION

BEXSERO (Meningococcal Group B Vaccine) is a sterile, white, opalescent, suspension for intramuscular injection. Each 0.5-mL dose of BEXSERO is formulated to contain 50 micrograms each of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), 25 micrograms of Outer Membrane Vesicles (OMV), 1.5 mg aluminum hydroxide (0.519 mg of Al³⁺), 3.125 mg sodium chloride, 0.776 mg histidine, and 10 mg sucrose at pH 6.4 – 6.7.

The NadA component is a fragment of the full-length protein derived from *N. meningitidis* strain 2996 (peptide 8 variant 2/3)⁵. The NHBA component is a recombinant fusion protein comprised of NHBA (peptide 2)⁵ and accessory protein 953 derived from *N. meningitidis* strains NZ98/254 and 2996, respectively. The fHbp component is a recombinant fusion protein comprised of fHbp (variant 1.1)⁵ and the accessory protein 936 derived from *N. meningitidis* strains MC58 and 2996, respectively. These 3 recombinant proteins are individually produced in *Escherichia coli* and purified through a series of

column chromatography steps. The OMV antigenic component is produced by fermentation of *N. meningitidis* strain NZ98/254 (expressing outer membrane protein PorA serosubtype P1.4)⁶, followed by inactivation of the bacteria by deoxycholate, which also mediates vesicle formation. The antigens are adsorbed onto aluminum hydroxide.

Each dose contains less than 0.01 micrograms kanamycin (by calculation).

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Protection against invasive meningococcal disease is conferred mainly by complement-mediated antibody-dependent killing of *N. meningitidis*. The effectiveness of BEXSERO was assessed by measuring serum bactericidal activity using human complement (hSBA).

NHBA, NadA, fHbp, and PorA are proteins found on the surface of meningococci and contribute to the ability of the bacterium to cause disease. Vaccination with BEXSERO leads to the production of antibodies directed against NHBA, NadA, fHbp, and PorA P1.4 (present in OMV). The susceptibility of serogroup B meningococci to complement-mediated antibody-dependent killing following vaccination with BEXSERO is dependent on both the antigenic similarity of the bacterial and vaccine antigens, as well as the amount of antigen expressed on the surface of the invading meningococci.

13 NONCLINICAL TOXICOLOGY

BEXSERO has not been evaluated for carcinogenic or mutagenic potential or impairment of male fertility.

14 CLINICAL STUDIES

The immunogenicity of BEXSERO following 2 doses was evaluated in individuals aged 11 through 24 years. Serum bactericidal antibodies were measured with hSBA assays using 3 strains selected to measure responses to one of 3 vaccine antigens, either fHbp, NadA, or PorA P1.4, prevalent among strains in the U.S. A suitable strain for assessing bactericidal activity of NHBA-specific antibodies was not available. Studies assessed the proportion of subjects who achieved a 4-fold or greater increase in hSBA titer for each of the 3 strains, and the proportion of subjects with a titer greater than or equal to the lower limit of quantitation (LLOQ) of the assay for all 3 strains (composite response). The LLOQ was defined as the lowest amount of the antibody in a sample that can be reliably quantified. Available data showed that baseline antibody titers across populations vary.

14.1 Immunogenicity

In a clinical trial conducted in Canada and Australia, adolescents aged 11 through 17 years received 2 doses of BEXSERO 1 month apart. The hSBA responses 1 month after the second dose are shown in Table 3 and Table 4.

Table 3. Bactericidal Antibody Response Rates following 2 Doses of BEXSERO Administered 1 Month Apart to Canadian and Australian Adolescents^a ≥4-Fold hSBA Response 1 Month Post Dose 2^{b,c}

Strain (Antigen)	n	%	95% CI
H44/76 (fHbp)	298	98	95, 99
5/99 (NadA)	299	99	98, 100
NZ98/254 (PorA P1.4)	298	39	33, 44

NCT 01423084.

Abbreviations: CI = Confidence interval; hSBA = Serum bactericidal activity measured using human complement; LLOQ = Lower limit of quantitation.

^a Evaluable Immunogenicity Population (aged 11 through 17 years).

^b ≥4-fold hSBA response is defined as: a post-vaccination hSBA ≥1:16 for participants with pre-vaccination hSBA <1:4, a post-vaccination titer at least 4-fold the LLOQ for participants with pre-vaccination hSBA ≥1:4 but < LLOQ, and a post-vaccination 4-fold rise for participants with pre-vaccination hSBA ≥LLOQ.

^c LLOQ = 1:16 for H44/76; 1:16 for 5/99; 1:8 for NZ98/254.

Table 4. Bactericidal Antibody Response Rates following 2 Doses of BEXSERO Administered 1 Month Apart to Canadian and Australian Adolescents^a - Composite hSBA Response^{b,c}

Time Point	n	%	95% CI
Baseline (pre-vaccination)	299	0	
1 Month Post Dose 2	298	63	57, 68

NCT 01423084.

Abbreviations: CI = Confidence interval; hSBA = Serum bactericidal activity measured using human complement; LLOQ = Lower limit of quantitation.

^a Evaluable Immunogenicity Population (aged 11 through 17 years).

^b LLOQ = 1:16 for H44/76; 1:16 for 5/99; 1:8 for NZ98/254.

^c Composite hSBA Response means hSBA ≥LLOQ for all 3 indicator Meningococcal B strains.

In a randomized, controlled clinical trial conducted in the U.K. among university students aged 18 through 24 years, hSBA responses in a subset of participants who received BEXSERO were measured 1 month and 11 months after the second dose (Table 5 and Table 6).

Table 5. Bactericidal Antibody Response Rates following 2 Doses of BEXSERO Administered 1 Month Apart to University Students in the U.K.^a ≥4-Fold hSBA Response 1 Month Post Dose 2^{b,c}

Strain (Antigen)	n	%	95% CI
H44/76 (fHbp)	148	78	71, 85
5/99 (NadA)	148	94	89, 97
NZ98/254 (PorA P1.4)	147	67	58, 74

NCT 01214850.

Abbreviations: CI = Confidence interval; hSBA = Serum bactericidal activity measured using human complement; LLOQ = Lower limit of quantitation.

^a Evaluable Immunogenicity Population (aged 18 through 24 years).

^b ≥4-fold hSBA response is defined as: a post-vaccination hSBA ≥1:16 for participants with pre-vaccination hSBA <1:4, a post-vaccination titer at least 4-fold the LLOQ for participants with pre-vaccination hSBA ≥1:4 but <LLOQ, and a post-vaccination 4-fold rise for participants with pre-vaccination hSBA ≥LLOQ.

^c LLOQ = 1:16 for H44/76; 1:8 for 5/99; 1:16 for NZ98/254.

Table 6. Bactericidal Antibody Response Rates following 2 Doses of BEXSERO Administered 1 Month Apart to University Students in the U.K.^a - Composite hSBA Response^{b,c}

Time Point	n	%	95% CI
------------	---	---	--------

Baseline (pre-vaccination)	186	24	18, 30
1 Month Post Dose 2	147	88	82, 93
11 Months Post Dose 2	136	66	58, 72

NCT 01214850.

Abbreviations: CI = Confidence interval; hSBA = Serum bactericidal activity measured using human complement; LLOQ = Lower limit of quantitation.

^a Evaluable Immunogenicity Population (aged 18 through 24 years).

^b LLOQ = 1:16 for H44/76; 1:8 for 5/99; 1:16 for NZ98/254.

^c Composite hSBA Response means hSBA \geq LLOQ for all 3 indicator Meningococcal B strains.

15 REFERENCES

1. NCT01272180 (V102_03).
2. NCT00661713 (V72P10).
3. NCT01214850 (V72_29).
4. NCT01423084 (V72_41).
5. Wang X, et al. *Vaccine*. 2011; 29:4739-4744.
6. Hosking J, et al. *Clin Vaccine Immunol*. 2007;14:1393-1399.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

BEXSERO is supplied as a 0.5-mL suspension in a glass prefilled syringe. The tip caps of the prefilled syringes contain natural rubber latex; the plungers are not made with natural rubber latex.

Product presentations for BEXSERO are listed in Table 7 below:

Table 7. Product Presentations for BEXSERO

Presentation	Carton NDC Number	Components
Pre-filled syringe		
Carton of 1 syringe	58160-976-06	0.5-mL single-dose prefilled syringe NDC 58160-976-02
Carton of 10 syringes	58160-976-20	0.5-mL single-dose prefilled syringe NDC 58160-976-02

16.2 Storage and Handling

Do not freeze. Discard if the vaccine has been frozen.

Store refrigerated, at 36°F to 46°F (2°C to 8°C).

Protect from light.

Do not use after the expiration date.

17 PATIENT COUNSELING INFORMATION

Provide the Vaccine Information Statement. These are available free of charge at the Centers for Disease Control and Prevention (CDC) website (<http://www.cdc.gov/vaccines>).

Inform patients, parents or guardians about:

- The importance of completing the immunization series.
- Reporting any adverse reactions to their healthcare provider.
- Register women who receive BEXSERO while pregnant in the pregnancy registry by calling 1-877-413-4759 [see *Use in Specific Populations (8.1)*].

BEXSERO and MENVEO are trademarks owned by or licensed to the GSK group of companies.

The other brand listed is a trademark owned by or licensed to its owner and is not owned by or licensed to the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.

Manufactured by **GSK Vaccines, Srl**

Bellaria-Rosia 53018, Sovicille (SI), Italy

U.S. License No. 1617

Distributed by **GlaxoSmithKline**

Research Triangle Park, NC 27709

©2018 GSK group of companies or its licensor.

BXS:3PI

PRINCIPAL DISPLAY PANEL

NDC 58160-976-20

Meningococcal Group B Vaccine

BEXSERO®

Rx Only

10 pre-filled syringes (1 Single dose (0.5 mL) per syringe)

For use in persons 10 years through 25 years of age

Suspension for intramuscular injection only

GlaxoSmithKline

Made in Italy

©2017 the GSK group of companies

490709_01 Rev. 7/17

NDC 58160-976-20

Rx Only

Meningococcal Group B Vaccine

BEXSERO®

10 pre-filled syringes (1 Single dose (0.5 mL) per syringe)

For use in persons 10 years through 25 years of age

Suspension for intramuscular injection only



Syringe Label

NDC 58160-976-02

490881

Meningococcal Group B Vaccine BEXSERO® 490881	Rx Only 1 dose (0.5 mL) For IM Use Only	NDC 58160-976-02	NDC 58160-976-02 BEXSERO®
		Lot:	Lot:
		Exp:	Exp:
		Mfd. by GSK Vaccines, Srl Bellaria-Rosia, Italy US Lic. No. 1617	

BEXSERO

neisseria meningitidis serogroup b nhba fusion protein antigen, neisseria meningitidis serogroup b fhbp fusion protein antigen and neisseria meningitidis serogroup b nada protein antigen injection, suspension

Product Information

Product Type	VACCINE	Item Code (Source)	NDC:58160-976
Route of Administration	INTRAMUSCULAR		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN (UNII: 28E911Y7AE) (NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN - UNII:28E911Y7AE)	NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN ANTIGEN	50 ug in 0.5 mL
NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN (UNII: 25DB599G64) (NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN - UNII:25DB599G64)	NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN ANTIGEN	50 ug in 0.5 mL
NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN (UNII: 1S25R442RS) (NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN - UNII:1S25R442RS)	NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN ANTIGEN	50 ug in 0.5 mL
NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE (UNII: 91523M4S24) (NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE - UNII:91523M4S24)	NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE	25 ug in 0.5 mL

Inactive Ingredients

Ingredient Name	Strength
ALUMINUM HYDROXIDE (UNII: 5QB0T2IUN0)	
SODIUM CHLORIDE (UNII: 451W47IQ8X)	
HISTIDINE (UNII: 4QD397987E)	
SUCROSE (UNII: C151H8M554)	
WATER (UNII: 059QF0K00R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:58160-976-06	1 in 1 CARTON		
1	NDC:58160-976-02	0.5 mL in 1 SYRINGE; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)		
2	NDC:58160-976-20	10 in 1 CARTON		
2	NDC:58160-976-02	0.5 mL in 1 SYRINGE; Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA125546	12/01/2016	

Labeler - GlaxoSmithKline Biologicals SA (372748392)

Revised: 5/2018

GlaxoSmithKline Biologicals SA